Skip to main content
    I

    Insight Molecular Diagnostics Inc. (IMDX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $3.06
    +0.27 (+9.68%)

    Market Cap: $91.30M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    34%(12/35)
    Avg Surprise
    -25.42%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.22
    Range$-0.24 - $-0.20
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.18-22.2%
    60d ago$-0.18-22.2%
    30d ago$-0.20-10.0%
    7d ago$-0.220.0%
    Current$-0.22
    Revenue Consensus
    $244280
    Range$100000 - $300000
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.21
    Range$-0.22 - $-0.21
    2 analysts
    Revenue Consensus
    $50720
    Range$-509280 - $790720
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.21---
    Sep 26EST
    		-$-0.22---
    Jun 26
    Reported Aug 10
    		$-0.23$-0.23+0.00%Beat+23.3%
    Mar 26
    Reported May 13
    		$-0.12N/A+53.85%Beat+47.8%
    Dec 25
    Reported Mar 26
    		$-0.72$-0.24-203.16%Miss+62.7%
    Sep 25
    Reported Nov 10
    		$-0.23$-0.24+4.17%Beat+76.5%
    Jun 25
    Reported Aug 11
    		$-0.30$-0.24-25.00%Miss+30.2%
    Mar 25
    Reported May 12
    		$-0.23$-0.25+8.00%Beat+88.9%
    Dec 24
    Reported Mar 24
    		$-1.93$-1.12-72.32%Miss-211.3%
    Sep 24
    Reported Nov 12
    		$-0.98$-0.44-122.73%Miss-34.2%
    Jun 24
    Reported Aug 8
    		$-0.43$-0.37-16.22%Miss-1175.0%
    Mar 24
    Reported Apr 12
    		$-2.07$-0.99-109.09%Miss+8.0%
    Sep 23
    Reported Nov 9
    		$-0.62$-0.78+20.51%Beat+74.5%
    Jun 23
    Reported Aug 10
    		$-0.73$-0.59-23.73%Miss+71.6%
    Mar 23
    Reported May 11
    		$0.04$-0.08+150.00%Beat+101.2%
    Dec 22
    Reported Mar 29
    		$-2.25$-1.60-40.63%Miss-476.9%
    Sep 22
    Reported Nov 10
    		$-2.43$-2.33-4.29%Miss+12.0%
    Jun 22
    Reported Aug 10
    		$-2.57$-2.00-28.50%Miss+0.4%
    Mar 22
    Reported May 11
    		$-3.24$-2.00-62.00%Miss-224.0%
    Dec 21
    Reported Mar 10
    		$-0.39$-0.12-217.33%Miss-333.3%
    Sep 21
    Reported Nov 9
    		$-2.76$-2.00-38.00%Miss-9.1%
    Jun 21
    Reported Aug 10
    		$-2.58$-1.84-40.22%Miss+2.3%
    Mar 21
    Reported May 17
    		$-1.00$-1.88+46.81%Beat+60.0%
    Dec 20
    Reported Mar 16
    		$-0.09$-0.11+16.28%Beat+40.0%
    Sep 20
    Reported Nov 12
    		$-2.53$-1.84-37.50%Miss-27.8%
    Jun 20
    Reported Jul 29
    		$-2.64$-2.05-28.78%Miss-36.1%
    Mar 20
    Reported May 12
    		$-2.50$-2.12-17.92%Miss-58.2%
    Dec 19
    Reported Mar 25
    		$-0.15$-0.09-66.67%Miss+90.6%
    Sep 19
    Reported Nov 14
    		$-1.98$-1.64-20.73%Miss-4.8%
    Jun 19
    Reported Aug 14
    		$-1.94$-1.72-12.79%Miss+22.7%
    Mar 19
    Reported Apr 1
    		$-1.58$-1.72+8.14%Beat+37.5%
    Sep 18
    Reported Nov 13
    		$-1.60$-1.73+7.51%Beat+38.5%
    Jun 18
    Reported Aug 14
    		$-1.89$-1.87-1.07%Miss+41.8%
    Mar 18
    Reported Apr 2
    		$-2.51$-2.40-4.58%Miss-25.5%
    Sep 17
    Reported Nov 14
    		$-2.53$-2.53+0.00%Beat-
    Jun 17
    Reported Aug 14
    		$-2.60$-2.33-11.59%Miss-
    Mar 17
    Reported Apr 28
    		$-3.25N/AN/ABeat-
    Dec 16
    Reported Feb 27
    		$-2.00$-2.00+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-2.35EV/EBITDAN/A
    Price/FCF-3.64xFCF Yield-27.46%
    Profitability
    Profit Margin0.00%Operating Margin-3815.00%
    ROE-23603.00%ROIC197.76%
    Financial Health
    Debt/Equity-0.08xInterest Coverage-502.66x
    Current Ratio2.00xQuick Ratio1.98x
    Trading Statistics
    Beta1.80Avg Volume321.72K
    52-Week High$8.5152-Week Low$2.42

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.26
    SMA 20$3.51
    SMA 50$3.93
    SMA 200$4.97
    EMA 10$3.21
    EMA 20$3.44
    EMA 50$3.88
    EMA 200$4.52

    MACD

    Line: -0.28Signal: -0.24Hist: -0.04

    ADX

    ADX: 43.5+DI: 5.6-DI: 24.5

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down96.0
    PSAR$3.57

    Bollinger Bands

    Upper Band$4.27
    Lower Band$2.74
    %B Position4355%(Upper)
    Band Width0.21

    RSI (14-Day)

    Neutral
    39.4

    Momentum Oscillators

    Stoch %K10.9
    Stoch %D10.0
    Williams %R-75.0
    ROC (10d)-11.8%
    Momentum-0.41
    CCI (20d)-126.0
    MFI (14d)36.2

    Volatility Measures

    ATR (14d)$0.37(12.1%)
    StdDev (20d)0.38
    Hist Vol104.4%(High)

    Volume Flow

    VWAP$2.99
    OBV-1.6M
    AD Line6.2M
    CMF (20d)-0.015

    Volume Metrics

    Avg Vol (20d)328.8K
    Vol Ratio0.5x
    VWMA (20d)$3.51

    Pivot Points

    R3$3.36
    R2$3.23
    R1$3.01
    Pivot Point$2.88
    S1$2.66
    S2$2.53
    S3$2.31

    Advanced Oscillators

    TSI-22.62
    Ultimate Osc44.4
    KST-186.75

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$239,000$32,000$1.14M$260,000$518,000$2.14M$1.49M$115,000$104,000$176,000$314,000$429,000
    Cost of Revenue$82,000$17,000$655,000$121,000$180,000$813,000$891,000$65,000$54,000$131,000$453,000$181,000
    Gross Profit$157,000$15,000$484,000$139,000$338,000$1.32M$595,000$50,000$50,000$45,000$-117,000$248,000
    Operating Expenses$11.56M$4.43M$23.92M$11.19M$10.18M$8.12M$34.22M$13.56M$4.68M$9.31M$16.06M$6.76M
    R&D$4.49M$4.95M$5.82M$3.88M$3.27M$2.92M$2.26M$2.82M$2.45M$2.31M$2.55M$2.19M
    SG&A$2.87M$2.99M$2.33M$2.54M$2.65M$3.12M$2.56M$2.56M$2.41M$2.67M$1.75M$2.49M
    Operating Income$-11,402,000$-4,413,000$-23,435,000$-11,048,000$-9,842,000$-6,799,000$-33,627,000$-13,515,000$-4,632,000$-9,267,000$-16,179,000$-6,513,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$20,000$23,000$26,000$29,000$25,000$29,000$30,000$31,000$8,000$15,000$13,000$14,000
    Income Before Tax$-11,260,000$-4,290,000$-22,955,000$-10,854,000$-9,742,000$-6,671,000$-33,511,000$-13,493,000$-4,530,000$-9,129,000$-15,992,000$-6,489,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-11,260,000$-4,290,000$-22,955,000$-10,854,000$-9,742,000$-6,671,000$-33,511,000$-13,493,000$-4,530,000$-9,129,000$-15,992,000$-6,489,000
    EBITDA$-10,575,000$-3,636,000$-22,366,000$-10,241,000$-9,158,000$-6,151,000$-32,918,000$-13,122,000$-4,196,000$-8,779,000$-15,654,000$-6,049,000
    EBIT$-11,240,000$-4,267,000$-22,929,000$-10,825,000$-9,717,000$-6,642,000$-33,481,000$-13,462,000$-4,522,000$-9,114,000$-15,979,000$-6,475,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IMDX

    News

    Mayo Clinic and Cleveland Clinic are among centers involved in a kidney test's FDA submission

    Insight Molecular Diagnostics (IMDX) has appointed Donnie Purto as Senior Vice President of Sales to lead commercialization efforts for its GraftAssureDx product. The diagnostic kit...

    Stock Titan•10/14/26•Neutral

    iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch

    Insight Molecular Diagnostics Inc. (iMDx) has appointed Donnie Purto as Senior Vice President of Sales to spearhead the commercialization of its GraftAssureDx product...

    GlobeNewswire•10/14/26•Bullish

    A kidney transplant researcher will discuss how blood tests could help tailor anti-rejection care

    Insight Molecular Diagnostics (IMDX) will participate in the virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026. The event will feature CEO Josh Riggs and Prof. Dr. Med. Klemens Budde...

    Stock Titan•10/13/26•Somewhat-Bullish

    iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings

    Insight Molecular Diagnostics Inc. (iMDx) announced its participation in the U.S. Bancorp I BTIG Kidney Health Forum on October 14...

    GlobeNewswire•10/12/26•Bullish

    iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings

    Insight Molecular Diagnostics Inc. (iMDx) announced its participation in the virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14...

    Yahoo! Finance Canada•10/12/26•Bullish

    IMDX Valuation and Fair Value

    P/E
    -2.4x
    P/FCF
    -3.6x
    P/B
    -5.3x
    See GNG's fair value

    IMDX Profitability: Margins, ROIC and FCF

    Gross margin
    47.6%
    Operating margin
    -3815.0%
    Net margin
    0.0%
    ROIC
    197.8%
    ROE
    -23603.0%
    FCF margin
    -1848.8%
    FCF yield
    -27.5%

    IMDX Competitors

    CompanyTicker
    Anixa Biosciences IncANIX
    OnKure Therapeutics, Inc.OKUR
    Pmv Pharmaceuticals IncPMVP
    Biomea Fusion IncBMEA
    Rani Therapeutics Holdings IncRANI
    Immunic IncIMUX
    Milestone Pharmaceuticals IncMIST
    Hyperfine IncHYPR

    Sector: Healthcare

    IMDX Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    1
    Buy
    2
    Hold
    2
    Sell
    0
    Strong Sell
    0

    IMDX Bull Case vs Bear Case

    Bull case

    • IMDX earns a 197.8% return on invested capital.
    • 60.0% of IMDX's analyst ratings are Buy or Strong Buy.

    Bear case

    • IMDX beat EPS estimates in 37.5% of its last 8 reported quarters.
    • IMDX's quarterly revenue changed -53.9% year over year.

    IMDX Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -44.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.22
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About IMDX

    Does IMDX pay dividends?

    Insight Molecular Diagnostics Inc. (IMDX) does not currently pay a regular dividend.

    What is IMDX's market cap?

    Insight Molecular Diagnostics Inc. (IMDX) has a market capitalization of $91.30M with a current stock price of $3.06.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In